Think Fabrazyme® first, regardless of gender, genotype, phenotype, antibody status, or life-stage1-4

    Fabrazyme has over 20 years of global real-world experience...

    ...being chosen for over 6000 patients worldwide regardless 
of their genotype, gender, or 
disease severity.1,5,6

    Fabrazyme showed a beneficial effect in females with Fabry disease...

    ...maintained normal kidney function as shown in a novel 
long-term trial of Fabrazyme outcomes in a large cohort (n=86) of females with Fabry disease.*7

    Fabrazyme maintained efficacy regardless of presence of antibodies...8

    ...approximately 83% (110 of 133) of adult patients receiving Fabrazyme developed antibodies:

    • 77% (102/133) of patients developed NAb that inhibited in vitro Fabrazyme catalytic activity, which declined over time
    • 6% (8/133) of patients developed NAb that inhibited cellular uptake1

    Over 90% of adult and pediatric patients achieved and maintained normal plasma GL-3 levels irrespective of developing antibodies.1

    In a retrospective study, no correlation was found between titers of anti-aGAL IgG antibodies and the onset of clinical events or rate of change in eGFR during treatment.8

    Fabrazyme is the first 
 and only ERT indicated 
 for patients aged 2 years 
 and older with confirmed Fabry disease...1

    ...with efficacy and safety outcomes in pediatric patients consistent with those seen in adults.1

Females with Fabry

Explore the importance of Fabrazyme for females
 

Children with Fabry

Learn why early diagnosis and treatment matters
 

Trusted experience

See the 20+ years of real-world evidence behind the first for Fabry
 

Michele, a female Fabrazyme® (agalsidase beta) patient

“At the time of my diagnosis, some of the medical field considered women to be only carriers of Fabry and usually asymptomatic. All these years later, now we know that women are not just carriers; many of
 us have multiple symptoms.”

Michelle, a real Fabrazyme

A woman wearing a yellow long sleeve shirt, a white skirt, and white shoes walking

IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION

WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS

Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy.

Initiate FABRAZYME in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. If a severe hypersensitivity reaction (e.g. anaphylaxis) occurs, discontinue FABRAZYME and immediately initiate appropriate medical treatment, including use of epinephrine. Inform patients of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis and to seek immediate medical care should symptoms occur [see Warnings and Precautions (5.1)].

 

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions Including Anaphylaxis

In clinical trials and post-marketing experience, approximately 1% of patients developed anaphylactic or severe hypersensitivity reactions, some life-threatening, during Fabrazyme infusion. Reactions have included localized angioedema (including swelling of the face, mouth, and throat), bronchospasm, hypotension, generalized urticaria, dysphagia, rash, dyspnea, flushing, chest discomfort, pruritus, and nasal congestion. Consider pretreating with antihistamines, antipyretics, and/or corticosteroids; however, reactions may still occur.

In Fabrazyme clinical trials, some patients developed IgE antibodies or skin test reactivity specific to Fabrazyme.

  • Higher incidences of hypersensitivity reactions were observed in adult patients with persistent anti-Fabrazyme antibodies, and in those with high antibody titers compared with antibody negative adult patients.
  • Consider testing for IgE antibodies in patients who experienced suspected hypersensitivity reactions and consider the risks and benefits of continued treatment in patients with anti-Fabrazyme IgE antibodies. Rechallenge of these patients should only occur under the direct supervision of qualified personnel, with appropriate medical support measures readily available.

Infusion-Associated Reactions

In Fabrazyme clinical trials, 59% of patients experienced infusion-associated reactions (IARs), some of which were severe. IARs are defined as those occurring on the same day as the infusion. The incidence of these reactions was higher in patients who were positive for anti-Fabrazyme antibodies than those negative for anti-Fabrazyme antibodies.

  • Consider pretreatment with antipyretics, antihistamines, and/or corticosteroids to reduce the risk of IARs; however, they may still occur.
  • If a mild or moderate IAR occurs, consider holding the infusion temporarily, decreasing the infusion rate, and/or reducing the Fabrazyme dosage. If a severe IAR occurs, discontinue Fabrazyme immediately and initiate appropriate medical treatment as needed. Assess the risks and benefits of readministering Fabrazyme and monitor patients closely if readministering.
  • Patients with advanced Fabry disease may have compromised cardiac function, which may predispose them to a higher risk of severe complications from IARs. Closely monitor patients with compromised cardiac function receiving Fabrazyme.

Common Adverse Reactions

Adverse reactions reported (≥20%) were upper respiratory tract infection, chills, pyrexia, headache, cough, paresthesia, fatigue, peripheral edema, dizziness, and rash.

Please see full Prescribing Information, including Boxed WARNING

IMPORTANT SAFETY INFORMATION

Show more

IMPORTANT SAFETY INFORMATION

WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS

Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy.

Initiate FABRAZYME in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. If a severe hypersensitivity reaction (e.g. anaphylaxis) occurs, discontinue FABRAZYME and immediately initiate appropriate medical treatment, including use of epinephrine. Inform patients of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis and to seek immediate medical care should symptoms occur [see Warnings and Precautions (5.1)].

 

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions Including Anaphylaxis

In clinical trials and post-marketing experience, approximately 1% of patients developed anaphylactic or severe hypersensitivity reactions, some life-threatening, during Fabrazyme infusion. Reactions have included localized angioedema (including swelling of the face, mouth, and throat), bronchospasm, hypotension, generalized urticaria, dysphagia, rash, dyspnea, flushing, chest discomfort, pruritus, and nasal congestion. Consider pretreating with antihistamines, antipyretics, and/or corticosteroids; however, reactions may still occur.

In Fabrazyme clinical trials, some patients developed IgE antibodies or skin test reactivity specific to Fabrazyme.

  • Higher incidences of hypersensitivity reactions were observed in adult patients with persistent anti-Fabrazyme antibodies, and in those with high antibody titers compared with antibody negative adult patients.
  • Consider testing for IgE antibodies in patients who experienced suspected hypersensitivity reactions and consider the risks and benefits of continued treatment in patients with anti-Fabrazyme IgE antibodies. Rechallenge of these patients should only occur under the direct supervision of qualified personnel, with appropriate medical support measures readily available.

Infusion-Associated Reactions

In Fabrazyme clinical trials, 59% of patients experienced infusion-associated reactions (IARs), some of which were severe. IARs are defined as those occurring on the same day as the infusion. The incidence of these reactions was higher in patients who were positive for anti-Fabrazyme antibodies than those negative for anti-Fabrazyme antibodies.

  • Consider pretreatment with antipyretics, antihistamines, and/or corticosteroids to reduce the risk of IARs; however, they may still occur.
  • If a mild or moderate IAR occurs, consider holding the infusion temporarily, decreasing the infusion rate, and/or reducing the Fabrazyme dosage. If a severe IAR occurs, discontinue Fabrazyme immediately and initiate appropriate medical treatment as needed. Assess the risks and benefits of readministering Fabrazyme and monitor patients closely if readministering.
  • Patients with advanced Fabry disease may have compromised cardiac function, which may predispose them to a higher risk of severe complications from IARs. Closely monitor patients with compromised cardiac function receiving Fabrazyme.

Common Adverse Reactions

Adverse reactions reported (≥20%) were upper respiratory tract infection, chills, pyrexia, headache, cough, paresthesia, fatigue, peripheral edema, dizziness, and rash.

Please see full Prescribing Information, including Boxed WARNING

INDICATION AND USAGE

Fabrazyme® is indicated for the treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease.

References: 1. Fabrazyme® (agalsidase beta). Prescribing Information 2024. 2. Vedder A et al. Genet Metab 2008;94(3):319–25. 3. Wraith JE et al. J Pediatr 2008;152:563–70. 4. Ortiz A et al. J Med Genet 2016;53(7):495–502. 5. Data on file. Genzyme Corporation. 6. Sanofi. Data on file. Based on estimated patient numbers based on publicly published revenue as of September 2022. 7. Wanner C et al. ESC Heart Failure 2020;7:825–834. 8. Bénichou B et al. Mol Genet Metab. 2009;96(1):4-12.